RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), systematically renamed CCL5 (C-C motif chemokine ligand 5), is a 68-amino acid chemokine of the CC family that serves as a master regulator of immune cell trafficking. Originally identified in 1988 by Schall et al. as a gene expressed in T lymphocytes upon activation, CCL5 recruits monocytes, memory T cells, eosinophils, basophils, dendritic cells, and natural killer cells to sites of inflammation through interactions with CCR1, CCR3, and CCR5 receptors.

Overview

CCL5 belongs to the CC chemokine subfamily, characterized by two adjacent cysteine residues near the N-terminus. It is produced by a wide array of cell types including T lymphocytes (particularly CD8+ memory T cells), macrophages, platelets, synovial fibroblasts, tubular epithelial cells, and certain tumor cells. CCL5 signals through three seven-transmembrane G-protein coupled receptors: CCR1 (monocytes, neutrophils), CCR3 (eosinophils, basophils, Th2 cells), and CCR5 (monocytes, macrophages, Th1 cells, activated T cells, dendritic cells, NK cells). Additionally, CCL5 binds glycosaminoglycans (GAGs) on endothelial surfaces, creating immobilized chemokine gradients essential for leukocyte arrest and transmigration under flow conditions.

The structure of CCL5 includes a flexible N-terminal region (residues 1-9) critical for receptor activation, followed by an N-loop that contacts the receptor extracellular domains, and a three-stranded antiparallel beta-sheet with a C-terminal alpha-helix. At low concentrations (<100 nM), CCL5 exists as dimers; at higher concentrations, it forms tetramers and higher-order oligomers that bind GAGs with increased affinity. This oligomerization is functionally important: obligate monomer CCL5 variants (E66S mutant) retain receptor binding but show impaired in vivo chemotactic activity, demonstrating that oligomer-GAG interactions are essential for physiological function.

Met-RANTES, created by adding a methionine residue to the N-terminus, was the first chemokine-derived receptor antagonist. This modification converts CCL5 from a CCR5 agonist to a potent antagonist, blocking HIV-1 entry and leukocyte recruitment. Met-RANTES served as proof-of-concept for targeting CCR5, directly informing the development of small-molecule CCR5 antagonists including maraviroc (the first FDA-approved CCR5 inhibitor in 2007) and the broader concept of chemokine receptor blockade in disease.

Mechanism of Action

CCL5 and its derivatives activate multiple signaling pathways through CCR receptors:

• Gi/o-coupled chemotaxis signaling: CCR5 activation by CCL5 couples to pertussis toxin-sensitive Gi proteins, activating PLC-beta (generating IP3/calcium flux and DAG/PKC), PI3K-gamma (generating PIP3, activating Akt and Rac GTPases), and releasing Gbetagamma subunits that drive cytoskeletal reorganization. The resulting actin polymerization, pseudopod extension, and integrin activation produce directional cell migration along the chemokine gradient. Oppermann, M. (2004) — Cell. Signal.

• HIV-1 co-receptor function of CCR5: R5-tropic HIV-1 gp120, after binding CD4, undergoes conformational change exposing the V3 loop that engages CCR5's N-terminus and extracellular loops. This triggers gp41-mediated membrane fusion. CCL5/RANTES blocks HIV entry through two mechanisms: direct competitive inhibition of gp120-CCR5 binding, and receptor internalization reducing surface CCR5 density. The CCR5-delta32 mutation (32bp deletion producing a truncated, non-functional receptor) confers near-complete resistance to R5-tropic HIV-1 in homozygotes and is found at ~10% allele frequency in northern European populations. Cocchi, F. et al. (1995) — Science

• Met-RANTES antagonism: The N-terminal methionine addition blocks the conformational change required for CCR5 activation. Met-RANTES binds CCR5 with affinity similar to native CCL5 but fails to trigger Gi coupling, calcium mobilization, or chemotaxis. Met-RANTES potently inhibits HIV-1 infection of macrophages and PBMCs at nanomolar concentrations. Proudfoot, A. E. et al. (1996) — J. Biol. Chem.

• Tumor-promoting CCL5/CCR5 signaling: In the tumor microenvironment, CCL5/CCR5 signaling on tumor cells activates mTOR, NF-kappaB, and STAT3, promoting proliferation, survival, and epithelial-mesenchymal transition (EMT). CCL5 produced by mesenchymal stem cells (MSCs) recruited to tumors acts in a paracrine fashion to enhance breast cancer metastasis. In pancreatic cancer, tumor-derived CCL5 recruits immunosuppressive Tregs and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment. Karnoub, A. E. et al. (2007) — Nature

• Anti-tumor CCL5 signaling: Paradoxically, CCL5 is also critical for anti-tumor immunity. Tumor-produced CCL5 recruits CD8+ cytotoxic T lymphocytes, NK cells, and dendritic cells to the tumor microenvironment, enabling immune recognition and killing. CCL5 expression correlates with improved survival in colorectal cancer, melanoma, and ovarian cancer when associated with Th1-polarized immune infiltrates. The Batf3-dependent conventional dendritic cell 1 (cDC1) population is recruited by CCL5 and XCL1, and its presence is essential for checkpoint immunotherapy responsiveness. Spranger, S. et al. (2017) — Cell

• Platelet-derived CCL5: Platelets are a major source of CCL5, released from alpha-granules upon activation. Platelet-derived CCL5 deposited on inflamed endothelium promotes monocyte arrest and transmigration. CCL5 heterodimer formation with CXCL4 (platelet factor 4) creates a synergistic signal for monocyte recruitment in atherosclerosis. von Hundelshausen, P. et al. (2005) — J. Exp. Med.

Research

Safety Profile

Native CCL5 is an endogenous chemokine and is not administered therapeutically. Safety considerations apply to CCL5-derived antagonists and CCR5-targeting agents:

Maraviroc (CCR5 antagonist): Generally well tolerated in HIV clinical trials and post-marketing surveillance. Common adverse effects include cough, upper respiratory infections, musculoskeletal symptoms, abdominal pain, and dizziness. Hepatotoxicity (elevated transaminases) has been reported rarely; an allergic component (rash, eosinophilia, elevated IgE) may precede hepatic injury. A theoretical concern with CCR5 blockade is increased susceptibility to infections (particularly West Nile virus, given CCR5's role in neuroinflammation) and impaired anti-tumor immunity. However, long-term follow-up of HIV patients on maraviroc and epidemiological studies of CCR5-delta32 carriers have not demonstrated significant immunodeficiency beyond HIV susceptibility changes. QT prolongation has not been observed at therapeutic doses.

Met-RANTES and chemokine-derived antagonists: Met-RANTES was primarily studied in vitro and in animal models. As a modified chemokine protein, immunogenicity (anti-drug antibodies) is a potential concern for chronic administration. Local injection site reactions may occur. Systemic CCR5 blockade risks are similar to maraviroc.

CCR5 blockade in oncology: The dual role of CCL5/CCR5 in the tumor microenvironment creates a theoretical risk that CCR5 antagonism could impair anti-tumor T cell trafficking in some contexts, particularly in "hot" tumors where CCL5 is mediating beneficial immune infiltration. Patient selection based on tumor immune phenotyping (CCR5 expression on tumor cells vs. immune cells) is likely necessary to avoid this paradox.

CCR5-delta32 homozygosity considerations: While protective against R5-tropic HIV, CCR5-delta32 homozygotes show increased susceptibility to West Nile virus encephalitis, suggesting that chronic CCR5 blockade may carry similar risk in endemic areas.

Clinical Research Protocols

• Maraviroc for HIV (approved): 300 mg orally twice daily (with or without food). Dose adjustment with CYP3A4 inhibitors (150 mg BID with protease inhibitors) or inducers (600 mg BID with efavirenz). Tropism testing (Trofile or genotypic) mandatory before initiation to confirm R5-tropic virus.
• Maraviroc for colorectal cancer (MARACON protocol): 300 mg orally twice daily for 4 weeks pre-operatively in patients with CCR5-positive liver metastases. Pre- and post-treatment biopsies for immune phenotyping (macrophage polarization M1/M2, T cell infiltration).
• Maraviroc for GVHD prophylaxis: 300 mg orally twice daily starting day -2 through day +30 after allogeneic stem cell transplantation, combined with standard tacrolimus + methotrexate prophylaxis.
• CCL5/CCR5 biomarker assessment in tumors: Multiplex immunohistochemistry for CCR5, CCL5, CD8, CD4, FoxP3 (Tregs), CD68/CD163 (macrophage polarization). RNA expression: CCL5 in tumor immune gene signature panels (e.g., T cell-inflamed GEP score used for pembrolizumab response prediction).
• Met-RANTES (research only): Preclinical dosing: 10-100 μg subcutaneous or intraperitoneal in mouse models. Not currently in clinical development due to availability of small-molecule CCR5 antagonists.

Pharmacokinetic Profile